Home › Funds › Keystone Financial Planning, Inc. › GSK

Keystone Financial Planning, Inc. position in GSK

GSK PLC · Health Care

Keystone Financial Planning, Inc. reported holding 211,232 shares of GSK (GSK PLC) in its Q3 2026 13F filing — a position valued at US$10.2M, representing 2.52% of its reported portfolio and ranking #8 among its reported holdings. Keystone Financial Planning, Inc. has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)211.23K sh
Reported value held$10.18M
Portfolio Weight2.52%
First reportedQ3 2023
Last changeAdd
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Keystone Financial Planning, Inc.'s GSK position evolved

Keystone Financial Planning, Inc. first disclosed a stake in GSK in Q3 2023 at 49,157 shares (US$1.8M). The position peaked in Q2 2026 at 195,590 shares, worth US$10.3M. Across 12 filings, Keystone Financial Planning, Inc. increased the stake 4 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q3 2026) shows 211,232 shares valued at US$10.2M — an increase of 15,642 shares quarter over quarter.. Notable position changes include a 3661% increase in Q4 2024 (shares rose 15% over the following quarter), a 98% trim in Q4 2025 (shares rose 13% over the following quarter), a 3115% increase in Q2 2026 (shares fell 8% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 49.16K $1.78M New
Q4 2023 46.23K $1.71M Reduce
Q1 2024 38.38K $1.65M Reduce
Q3 2024 6.06K $247.73K New
Q4 2024 227.91K $7.71M Add
Q1 2025 228.89K $8.87M Hold
Q2 2025 229.12K $8.80M Hold
Q3 2025 227.46K $9.82M Reduce
Q4 2025 4.65K $228.13K Reduce
Q1 2026 6.08K $335.78K Add
Q2 2026 195.59K $10.25M Add
Q3 2026 211.23K $10.18M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GSK and 13F data

GSK (GSK PLC) is a Health Care company. 23 other funds we track also report a position in GSK — the largest reported positions include Dodge & Cox (US$2.53B), DODGE & COX (US$2.53B), PRIMECAP MANAGEMENT CO/CA/ (US$1.32B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GSK

All GSK fund holders →

FAQ

How long has Keystone Financial Planning, Inc. held GSK?

Keystone Financial Planning, Inc. has disclosed GSK holdings in 12 of the last 13 reported quarters, going back to Q3 2023.

What is Keystone Financial Planning, Inc.'s current position in GSK?

As of Q3 2026, Keystone Financial Planning, Inc. holds 211.23K shares of GSK (GSK PLC), valued at $10.18M, representing 2.52% of its reported portfolio and ranking #8.

Has Keystone Financial Planning, Inc. been buying or selling GSK?

In the latest 13F filing (Q3 2026), Keystone Financial Planning, Inc. increased its position in GSK. The position peaked in Q2 2026 at 195.59K shares.

Which other funds hold GSK?

Other major institutional holders of GSK include Dodge & Cox, DODGE & COX, PRIMECAP MANAGEMENT CO/CA/, among 23 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.